News
GLYC
2.030
-6.02%
-0.130
Weekly Report: what happened at GLYC last week (0408-0412)?
Weekly Report · 4d ago
GLYC, APLD and AUTL are among after hour movers
Seeking Alpha · 04/11 21:00
NIU, HEAR and SGH are among after hour movers
On the Move NIU, HEAR and SGH are among after hour movers. Tilray Brands (TLRY) and Farmer Brothers Company (FARM) are among the biggest gainers. SMART Global Holdings (SGH) and WD-40 Company are the biggest losers.
Seeking Alpha · 04/09 20:59
Weekly Report: what happened at GLYC last week (0401-0405)?
Weekly Report · 04/08 12:03
Glycomimetics: Statement of changes in beneficial ownership of securities
Press release · 04/02 21:58
12 Health Care Stocks Moving In Tuesday's After-Market Session
OneMedNet (NASDAQ:ONMD) shares moved upwards by 75.9% to $1.39 during Tuesday's after-market session. Aesthetic Medical Intl shares rose 43.48% and Sight Sciences shares rose 20.77%. Losers Enveric Biosciences, Acorda Therapeutics and Cutera were among the losers.
Benzinga · 04/02 20:31
Weekly Report: what happened at GLYC last week (0325-0329)?
Weekly Report · 04/01 11:59
Analysts’ Top Healthcare Picks: Praxis Precision Medicines (PRAX), GlycoMimetics (GLYC)
3 analysts have maintained Buy ratings on Praxis Precision Medicines, GlycoMimetics and Radnet. Truist Financial analyst Joon Lee maintained a Buy rating on the Healthcare sector stock today. The 3 analysts also have bullish sentiments on Radnet and Glycomimetics. The top 3 stocks recommended by analysts in the Healthcare Sector.
TipRanks · 03/28 12:20
Positive Outlook for GlycoMimetics: Buy Rating Affirmed Amid Anticipated Pivotal Trial Results and Strategic Growth Initiatives
TipRanks · 03/28 01:25
12 Health Care Stocks Moving In Wednesday's After-Market Session
Avalo Therapeutics (NASDAQ:AVTX) shares moved upwards by 215.8% to $15.0 during Wednesday's after-market session. The company's Q4 earnings report came out today. Fresh2 Group stock rose upwards by 5.26% as well.
Benzinga · 03/27 20:31
GlycoMimetics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/27 17:52
GlycoMimetics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Dow Jones · 03/27 17:52
Buy Recommendation for GlycoMimetics Based on Promising Upro Drug Prospects and Strong Pipeline
TipRanks · 03/27 16:35
Analysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Perspective Therapeutics (CATX)
TipRanks · 03/27 16:30
GLYC Stock Earnings: GlycoMimetics Beats EPS for Q4 2023
GlycoMimetics reported earnings per share of -14 cents. This was above the analyst estimate for EPS of -15 cents. The company reported revenue of $10,000. The stock was down 2.7% after the market closed on Wednesday.
Investorplace · 03/27 15:53
Buy Rating on GlycoMimetics Backed by Strong Financials and Promising Phase 3 Trial of Uproleselan
TipRanks · 03/27 15:35
GlycoMimetics Inc reports results for the quarter ended in December - Earnings Summary
GlycoMimetics Inc reports results for the quarter ended in December. Reported revenue was zero; analysts expected zero. The company reported a quarterly loss of $9.08 million. Shares had risen by 20.8% this quarter. The average analyst rating on the shares is "buy"
Reuters · 03/27 13:32
Options Volatility and Implied Earnings Moves Today, March 27, 2024
TipRanks · 03/27 12:05
GlycoMimetics GAAP EPS of -$0.14 beats by $0.01
Seeking Alpha · 03/27 11:08
*GlycoMimetics 4Q Revenue From Collaboration, License Agreements $10M >GLYC
Dow Jones · 03/27 11:03
More
Webull provides a variety of real-time GLYC stock news. You can receive the latest news about Glycomimetics through multiple platforms. This information may help you make smarter investment decisions.
About GLYC
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Its drug candidates include Uproleselan, GMI-1687, Galectin Antagonists and GMI-1359. It is developing Uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is a drug candidate that simultaneously targets both E-selectin and a chemokine receptor (CXCR4).